potential COVID-19 treatments - versus control - for COVID 19 outpatients pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.58 [0.29, 1.15]< 17%11 studies (11/-)94.0 %some concernlow moderatecrucial-
deaths 0.75 [0.54, 1.04]< 10%26 studies (26/-)95.6 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.80 [0.43, 1.50]< 10%1 study (1/-)75.7 %some concernnot evaluable moderatecrucial-
hospitalization or death 0.53 [0.40, 0.69]< 168%20 studies (20/-)100.0 %some concerncritical moderatecrucial-
A EFFACER PCR-negative (end of follow-up) 0.91 [0.57, 1.46]> 10%1 study (1/-)34.7 %some concernnot evaluable moderateimportant-
clinical deterioration 0.77 [0.62, 0.97]< 154%9 studies (9/-)98.7 %some concernserious moderateimportant-
clinical improvement 1.12 [1.05, 1.19]> 10%7 studies (7/-)100.0 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.13 [0.91, 1.40]> 10%3 studies (3/-)86.6 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 1.28 [0.79, 2.10]> 10%1 study (1/-)84.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.08 [0.98, 1.19]> 10%2 studies (2/-)94.1 %lownot evaluable highimportant-
clinical improvement (7-day) 1.32 [0.44, 3.94]> 147%2 studies (2/-)69.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.07 [1.00, 1.16]> 10%3 studies (3/-)97.0 %some concernnot evaluable moderateimportant-
hospitalization 0.75 [0.64, 0.87]< 118%24 studies (24/-)100.0 %some concernlow moderateimportant-
mechanical ventilation 0.85 [0.55, 1.30]< 10%6 studies (6/-)77.6 %some concernnot evaluable moderateimportant-
symptomatic Covid-19 0.56 [0.31, 1.00]< 10%1 study (1/-)97.6 %some concernnot evaluable moderateimportant-
viral clearance 0.93 [0.77, 1.11]> 145%8 studies (8/-)21.4 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.79 [0.59, 1.07]> 148%3 studies (3/-)6.3 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.00 [0.76, 1.31]> 143%9 studies (9/-)50.0 %some concernnot evaluable moderateimportant-
emergency room observation for > 6 hours or hospitalization 0.64 [0.47, 0.87]< 10%1 study (1/-)99.8 %some concernnot evaluable moderatenon important-
ICU admission 0.72 [0.45, 1.15]< 10%4 studies (4/-)91.5 %some concernnot evaluable moderatenon important-
recovery 1.10 [0.90, 1.35]> 152%3 studies (3/-)82.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE leading to drug discontinuation 0.79 [0.37, 1.69]< 160%4 studies (4/-)72.9 %some concernnot evaluable moderateimportant-
emergent treatment-resistant variants 0.64 [0.08, 4.94]< 167%2 studies (2/-)66.3 %some concernnot evaluable moderateimportant-
related AE (TRAE) 1.74 [1.51, 2.01]< 10%2 studies (2/-)0.0 %lownot evaluable highimportant-
related SAE (TRSAE) 1.01 [0.25, 4.05]< 10%1 study (1/-)49.6 %lownot evaluable highimportant-
serious adverse events 0.66 [0.49, 0.89]< 120%7 studies (7/-)99.6 %some concernnot evaluable moderateimportant-
adverse events 1.59 [0.86, 2.93]< 194%10 studies (10/-)6.8 %some concernlow moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.